Efficacy of low-dose erlotinib as maintenance therapy in patients of lung adenocarcinoma with EGFR mutation

Efficacy of low-dose erlotinib as maintenance therapy in patients of lung adenocarcinoma with EGFR mutation - Efficacy of low-dose erlotinib as maintenance therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005468

Enrollment

Registered

2011-04-19

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung adenocarcinoma

Interventions

Low-dose erlotinib (25mg/day) is administrated after treatment of platinum based combination regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Lung adenocarcinoma with EGFR mutation is obtained pathologically or cytologically. (2)Patient with normal swallowing function to take erlotinib. (3)WBC>3000 Platelet<100000 GOT, GPT<2xthe upper limit of the normal range T-Bil<the upper limit of normal range sCr<1.5xupper limit of normal range (4)Patinet without interstitial pneumonitis and lung fibrosis (5)patient without treatment history of EGFR-TKI (6)Performance status;PS<4 (7)Age>19, age<85 (8)Informed consent is obtained from the patient

Exclusion criteria

Exclusion criteria: (1) Patient with severe complication (2) Patient with symptomatic brain metastasis (3) Patient with double cancer (4) Pregnant, breast feeding patient. Patient with possibility of pregnant (5) Patient with diarrhea (6) History of myocardial infarction within 3 months (7) Unsuitable patient for this study in opinion of doctor in charge

Design outcomes

Primary

Measure	Time frame
Response rate (CR+PR)	—

Secondary

Measure	Time frame
Overall survival, progression-free survival, Disease control rate, frequency of adverse events, QOL	—

Countries

Japan

Contacts

Public ContactSatoshi Hirano

Funabashi municipal medical center Medical oncology

shirano@mmc.funabashi.chiba.jp+81-47-438-3321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026